Form 8-K - Current report:
SEC Accession No. 0001104659-25-098487
Filing Date
2025-10-10
Accepted
2025-10-10 06:11:04
Documents
16
Period of Report
2025-10-08
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2528385d1_8k.htm   iXBRL 8-K 35121
2 EXHIBIT 1.1 tm2528385d1_ex1-1.htm EX-1.1 317708
3 EXHIBIT 4.1 tm2528385d1_ex4-1.htm EX-4.1 83364
4 EXHIBIT 5.1 tm2528385d1_ex5-1.htm EX-5.1 9523
8 GRAPHIC tm2528385d1_ex5-1img001.jpg GRAPHIC 10445
  Complete submission text file 0001104659-25-098487.txt   730570

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA apge-20251008.xsd EX-101.SCH 3044
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE apge-20251008_lab.xml EX-101.LAB 34239
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apge-20251008_pre.xml EX-101.PRE 22378
18 EXTRACTED XBRL INSTANCE DOCUMENT tm2528385d1_8k_htm.xml XML 3815
Mailing Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453
Business Address 221 CRESCENT ST. BUILDING 17, SUITE 102B WALTHAM MA 02453 650-394-5230
Apogee Therapeutics, Inc. (Filer) CIK: 0001974640 (see all company filings)

EIN.: 934958665 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41740 | Film No.: 251386223
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)